A Fresh Look at Medical Device Maker DexCom After Earnings

The shares gapped higher Friday to refresh the uptrend.

Shares of DexCom (DXCM) gapped higher Friday after the company reported better-than-anticipated quarterly numbers Thursday evening.

In our October 12 review of DXCM we wrote that "The price of DXCM could pull back a little bit further in the short run. Traders who are long should continue to hold with sell stops at $85. We probably will see further sideways price action before an attempt at further gains." 

Let's check the charts again.

In the updated daily bar chart of DXCM, below, we can see that the shares traded sideways and dipped towards the rising 50-day moving average line in the days after our October 12 review. Prices gapped higher Friday to refresh the uptrend. Our suggested sell stop at $85 was not reached. DXCM is firmly above the now bottoming 200-day moving average line.

The On-Balance-Volume (OBV) line has been moving sideways since May and is likely to turn higher now. The Moving Average Convergence Divergence (MACD) oscillator is bullish.

 

In the weekly Japanese candlestick chart of DXCM, below, we see an improving picture. Prices are trading above the bottoming 40-week moving average line.

 

The weekly OBV line is still in a decline from November. The MACD oscillator is moving up to the zero line and we could soon see a buy signal.

 

 

In this daily Point and Figure chart of DXCM, below, we can see an upside price target in the $164 area.

 

 

In this weekly Point and Figure chart of DXCM, below, an upside price target of only $154 is shown.

 

 

Bottom-line strategy: Continue to hold longs from previous recommendations. The shares are likely to trade sideways in the days ahead to unwind  overbought readings. Aggressive traders could use this anticipated period of sideways action to add to longs. The $154 area is our next price target.

 

Employees of TheStreet are prohibited from trading individual securities.